$CTMX
CytomX Therapeutics Inc

2018 Q1 Form 10-Q Financial Statement

#000156459018012382 Filed on May 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1 2016 Q4
Revenue $14.18M $11.65M $6.272M
YoY Change 21.72% 424.2% 215.49%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.360M $5.690M $5.150M
YoY Change 29.35% 12.9% 28.43%
% of Gross Profit
Research & Development $22.46M $14.58M $15.35M
YoY Change 54.08% 9.06% 61.58%
% of Gross Profit
Depreciation & Amortization $400.0K $400.0K $500.0K
YoY Change 0.0% 0.0% 66.67%
% of Gross Profit
Operating Expenses $29.81M $20.27M $20.50M
YoY Change 47.11% 10.12% 51.74%
Operating Profit -$15.63M -$8.614M
YoY Change 81.45% -46.77%
Interest Expense $1.380M $206.0K $190.0K
YoY Change 569.9% -41.64% 171.43%
% of Operating Profit
Other Income/Expense, Net -$140.0K $120.0K -$20.00K
YoY Change -216.67% 531.58% -33.33%
Pretax Income -$14.40M -$8.258M -$14.06M
YoY Change 74.32% -48.47% 22.37%
Income Tax $1.098M -$1.000K -$30.00K
% Of Pretax Income
Net Earnings -$15.49M -$8.257M -$14.03M
YoY Change 87.63% -48.49% 22.16%
Net Earnings / Revenue -109.23% -70.86% -223.74%
Basic Earnings Per Share
Diluted Earnings Per Share -$400.8K -$226.1K -$385.1K
COMMON SHARES
Basic Shares Outstanding 36.52M 36.40M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $361.5M $162.5M $181.9M
YoY Change 122.46% -10.02% -2.57%
Cash & Equivalents $142.2M $85.66M $104.6M
Short-Term Investments $219.3M $76.90M $77.30M
Other Short-Term Assets $5.500M $4.100M $3.900M
YoY Change 34.15% 20.59% 69.57%
Inventory
Prepaid Expenses
Receivables $100.0K $300.0K $2.159M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $367.0M $166.9M $188.1M
YoY Change 119.91% -9.54% -0.85%
LONG-TERM ASSETS
Property, Plant & Equipment $4.622M $4.600M $4.392M
YoY Change 0.48% 31.43% 26.17%
Goodwill $949.0K $949.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.300M $3.700M $2.973M
YoY Change -37.84% 1097.41% 716.76%
Total Long-Term Assets $9.469M $11.00M $10.98M
YoY Change -13.92% 47.61% 47.18%
TOTAL ASSETS
Total Short-Term Assets $367.0M $166.9M $188.1M
Total Long-Term Assets $9.469M $11.00M $10.98M
Total Assets $376.5M $177.9M $199.1M
YoY Change 111.64% -7.32% 0.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.300M $3.700M $6.596M
YoY Change 43.24% -25.37% 40.43%
Accrued Expenses $16.30M $6.300M $8.824M
YoY Change 158.73% 32.97% 79.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $69.70M $37.10M $35.77M
YoY Change 87.87% 118.2% 127.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.055M $66.50M $566.0K
YoY Change -96.91% 7.78% 185.86%
Total Long-Term Liabilities $2.055M $66.50M $566.0K
YoY Change -96.91% 7.78% 185.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.70M $37.10M $35.77M
Total Long-Term Liabilities $2.055M $66.50M $566.0K
Total Liabilities $326.8M $104.1M $120.6M
YoY Change 213.94% 31.38% 69.58%
SHAREHOLDERS EQUITY
Retained Earnings -$245.9M -$176.4M
YoY Change 50.14%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.65M $73.80M $78.48M
YoY Change
Total Liabilities & Shareholders Equity $376.5M $177.9M $199.1M
YoY Change 111.61% -7.34% 0.97%

Cashflow Statement

Concept 2018 Q1 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$15.49M -$8.257M -$14.03M
YoY Change 87.63% -48.49% 22.16%
Depreciation, Depletion And Amortization $400.0K $400.0K $500.0K
YoY Change 0.0% 0.0% 66.67%
Cash From Operating Activities -$14.61M -$19.10M $2.000M
YoY Change -23.5% 247.27% -124.39%
INVESTING ACTIVITIES
Capital Expenditures $751.0K $944.0K -$600.0K
YoY Change -20.44% 188.69% 200.0%
Acquisitions
YoY Change
Other Investing Activities -$22.60M $200.0K $43.00M
YoY Change -11400.0% -98.56% -184.81%
Cash From Investing Activities -$23.38M -$800.0K $42.50M
YoY Change 2822.88% -105.88% -183.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.602M 900.0K 500.0K
YoY Change 189.11% -99.39%
NET CHANGE
Cash From Operating Activities -14.61M -19.10M 2.000M
Cash From Investing Activities -23.38M -800.0K 42.50M
Cash From Financing Activities 2.602M 900.0K 500.0K
Net Change In Cash -35.39M -18.98M 45.00M
YoY Change 86.45% -334.36% 91.49%
FREE CASH FLOW
Cash From Operating Activities -$14.61M -$19.10M $2.000M
Capital Expenditures $751.0K $944.0K -$600.0K
Free Cash Flow -$15.36M -$20.04M $2.600M
YoY Change -23.35% 243.98% -132.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5474000
CY2018Q1 us-gaap Assets Current
AssetsCurrent
367031000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4622000
CY2018Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1568000
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1604000
CY2018Q1 us-gaap Goodwill
Goodwill
949000
CY2018Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1355000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
397644000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2055000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4205000
CY2018Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
1035000
CY2017Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
69896000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1897000
CY2018Q1 us-gaap Liabilities
Liabilities
326815000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
49647000
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
295744000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
289454000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-228000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-94000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245870000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219465000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38903699
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38478560
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38903699
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38478560
CY2017Q4 us-gaap Assets
Assets
397644000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
376462000
CY2017Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
477000
CY2018Q1 us-gaap Revenues
Revenues
14184000
CY2017Q1 us-gaap Revenues
Revenues
11653000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22458000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14576000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7356000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5691000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
29814000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
20267000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15630000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8614000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1375000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
236000
CY2018Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
14184000
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
11176000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-140000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
120000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14395000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8258000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1098000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15493000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-8257000
CY2018Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.40
CY2017Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.23
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38647878
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36538869
CY2018Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-134000
CY2017Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-73000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15627000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8330000
CY2017Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
CY2018Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
36000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
376000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
395000
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
261000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-203000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3688000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2747000
CY2017Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10058000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1946000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-99000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1122000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
222000
CY2018Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
20000
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-220000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1115000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2825000
CY2018Q1 ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
1145000
CY2017Q1 ctmx Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
-1809000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14134000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11583000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14612000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19086000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
751000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
944000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
48132000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
40094000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
25500000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
40250000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-23383000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-788000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2602000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
891000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2602000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
891000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35393000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18983000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
178465000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105562000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143072000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86579000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
391000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
230000
CY2018Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the Business</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapeutics. The Company is pioneering a novel class of investigational antibody therapeutics, based on its Probody&#8482; therapeutic technology platform, for the treatment of cancer. The Probody therapeutic approach is designed to more specifically target antibody therapeutics to the tumor microenvironment and reduce drug activity in healthy tissue and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</p></div>
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p></div>
CY2018Q1 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</p></div>
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85662000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104645000
CY2017Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2016Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2018Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
351323000
CY2018Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
203000
CY2018Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
351120000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
361986000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
67000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
361919000
CY2018Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
0
CY2018Q1 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
12381000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7055207
CY2018Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0763
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7199679
CY2017Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
10068000
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2140000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4526000
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1558000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1523000
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
256000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
265000
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
305263000
CY2018Q1 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
10912000
CY2018Q1 us-gaap Deferred Revenue Refund Payments1
DeferredRevenueRefundPayments1
14134000
CY2018Q1 us-gaap Deferred Revenue
DeferredRevenue
302041000
CY2018Q1 ctmx Royalty Obligations Future Minimum Payments Due
RoyaltyObligationsFutureMinimumPaymentsDue
150000
CY2018Q1 ctmx License Termination Period
LicenseTerminationPeriod
P60D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6503458
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1261400
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
425139
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
33764
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7305955
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3600751
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.157
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
26.215
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.122
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.491
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.360
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.957
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3688000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2747000
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q1 ctmx Tax Cuts And Jobs Act Accounting Complete True False
TaxCutsAndJobsActAccountingCompleteTrueFalse
false
CY2018Q1 ctmx Tax Cuts And Jobs Act Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActIncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-18-012382-index-headers.html Edgar Link pending
0001564590-18-012382-index.html Edgar Link pending
0001564590-18-012382.txt Edgar Link pending
0001564590-18-012382-xbrl.zip Edgar Link pending
ctmx-10q_20180331.htm Edgar Link pending
ctmx-20180331.xml Edgar Link completed
ctmx-20180331.xsd Edgar Link pending
ctmx-20180331_cal.xml Edgar Link unprocessable
ctmx-20180331_def.xml Edgar Link unprocessable
ctmx-20180331_lab.xml Edgar Link unprocessable
ctmx-20180331_pre.xml Edgar Link unprocessable
ctmx-ex311_9.htm Edgar Link pending
ctmx-ex312_7.htm Edgar Link pending
ctmx-ex321_6.htm Edgar Link pending
ctmx-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending